STOCK TITAN

Guardant Health, Inc. - $GH STOCK NEWS

Welcome to our dedicated page for Guardant Health news (Ticker: $GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.

Guardant Health, Inc. (symbol: GH) is a pioneering biotechnology company headquartered in Redwood City, California. The company specializes in liquid-based cancer tests, providing innovative diagnostic tools for both clinical and research purposes. Guardant Health is renowned for its comprehensive liquid biopsy solutions, which offer non-invasive methods to access and sequence tumor DNA.

The company's flagship products include:

  • Guardant360 LDT: A liquid biopsy test that assists in treatment selection for advanced-stage cancer patients.
  • Guardant360 CDx: An FDA-approved companion diagnostic for several targeted therapies, ensuring precise treatment plans.
  • Guardant OMNI: A broad gene panel designed for immuno-oncology research, aiding in the understanding of cancer's genetic underpinnings.
  • Reveal: Launched in 2021, this tumor-agnostic molecular residual disease (MRD) test helps monitor cancer recurrence or residual disease at the molecular level.
  • Shield: Introduced in 2022, this lab-developed test offers a non-invasive screening option for colorectal cancer (CRC).

Guardant Health's cutting-edge technologies have been widely adopted by thousands of oncologists globally, benefiting tens of thousands of advanced cancer patients. The company has made significant strides in early cancer detection, with ongoing projects that promise to deliver profound impacts on patient care.

Financially, Guardant Health has raised over $500 million from prestigious investors such as Sequoia Capital, Khosla Ventures, Orbimed, and SoftBank. This substantial backing underscores the confidence in Guardant's potential to revolutionize cancer diagnostics and treatment.

In addition to its product offerings, Guardant Health provides research development services, including regulatory approval consultancy and clinical trial referrals. These services are designed to support the seamless integration of their diagnostic tools into clinical practice and research settings.

Stay updated with the latest news and developments about Guardant Health, Inc. as the company continues to push the boundaries of cancer diagnostics and treatment.

Rhea-AI Summary

Guardant Health has launched an upgraded version of its Guardant360 TissueNext test, which now identifies 498 genes or cancer biomarkers. This expanded gene panel helps oncologists find more targeted therapies for patients with advanced cancer. Additionally, operational improvements have streamlined the workflow, reducing the time to results to less than two weeks. The test is covered by Medicare for patients with advanced solid tumors. Guardant Health aims to improve patient outcomes by providing more comprehensive gene coverage. This new test can be ordered either alone or in combination with Guardant360 CDx to support guideline-recommended genomic profiling for advanced breast and lung cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.12%
Tags
none
-
Rhea-AI Summary

Guardant Health (NASDAQ:GH), a precision oncology company, has been named to the TIME100 Most Influential Companies list. This recognition comes due to the company's impact, innovation, ambition, and success.

Guardant was included in the Innovators section, which features 20 companies from various industries. Key milestones for Guardant include achieving 500 peer-reviewed publications and delivering 500,000 patient tests.

Additionally, the FDA’s Medical Devices Advisory Committee has recommended approval for Shield™, Guardant's blood test for colorectal cancer screening. The FDA's decision is expected later this year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
none
-
Rhea-AI Summary

Guardant Health (Nasdaq: GH) will present data from 16 studies at the 2024 ASCO Annual Meeting, May 31-June 4 in Chicago. The studies highlight the impact of Guardant's blood tests and real-world data on precision oncology and cancer screening. Key presentations include interim data from the RADIOHEAD study showing correlations between epigenomic biomarkers and immunotherapy responses across 13 cancer types.

Presentations will cover the utility of ctDNA for therapy response monitoring, the use of the GuardantINFORM clinical-genomic database to study tumor drivers and resistance, and applications of genomic and epigenomic biomarkers in cancer treatment. Featured studies focus on racial differences in genomic profiles in metastatic breast cancer and the quantification of tumor fractions using the Guardant Infinity platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.29%
Tags
conferences
Rhea-AI Summary

The FDA's Molecular and Clinical Genetics Panel has strongly recommended the approval of Guardant Health's Shield™ blood test for colorectal cancer (CRC) screening in adults aged 45 and older at average risk. The panel's vote was 8 to 1 for safety, 6 to 3 for effectiveness, and 7 to 2 for benefits outweighing risks. Shield aims to improve CRC screening rates by offering a non-invasive alternative to stool-based tests. Shield demonstrated 83% sensitivity and 90% specificity for advanced neoplasia in the pivotal ECLIPSE study, aligning with existing non-invasive tests. The FDA is expected to make its decision later this year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.37%
Tags
-
Rhea-AI Summary

Guardant Health (Nasdaq: GH) announced a temporary halt in trading of its stock on Nasdaq. This pause precedes a important meeting of the FDA's Molecular and Clinical Genetics Panel, which will review the premarket approval application for Shield™, Guardant Health’s blood test aimed at screening colorectal cancer in average-risk adults. The panel meeting, starting at 9:30 a.m. ET, will provide independent expert advice to the FDA to support its decision-making process.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Guardant Health (Nasdaq: GH), a precision oncology company, announced its participation in three upcoming investor conferences.

These include the William Blair 44th Annual Growth Stock Conference in Chicago on June 4, the Jefferies Global Healthcare Conference in New York on June 5, and the Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, Florida on June 11.

Live and archived webcasts of these sessions will be available on Guardant Health's website under the 'Investors' section.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

Guardant Health announced EU IVDR certification for its Guardant360 CDx liquid biopsy, allowing comprehensive genomic profiling across all solid cancers.

Certification by TÜV SÜD provides a significant milestone, ensuring compliance with stricter EU regulatory standards. This enables broader adoption and faster access to genomic profiling, aiding personalized treatment for advanced cancer patients.

Guardant360 CDx identifies somatic mutations using a blood sample, facilitating targeted therapies for non-small cell lung and breast cancer.

Clinical studies suggest that targeted therapies result in improved progression-free survival and higher response rates.

Adoption of genomic profiling with IVDR-certified liquid biopsy can address challenges like insufficient tissue for molecular profiling, ultimately benefiting more cancer patients.

Since its introduction, Guardant360 has been widely accepted, with over 500,000 tests performed and more than 400 peer-reviewed publications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.84%
Tags
none
-
Rhea-AI Summary

Guardant Health (Nasdaq: GH) announced on April 22, 2024, that its Compensation Committee has approved the granting of restricted stock units (RSUs) and non-qualified stock options to new non-executive employees under its 2023 Employment Inducement Incentive Award Plan. This move, compliant with Nasdaq Listing Rule 5635(c)(4), involves RSUs representing 215,601 shares of common stock to 94 employees and stock options to purchase 98,076 shares to three employees. The RSUs and stock options have a vesting schedule tied to continued employment, with stock options priced at $24.00 per share, the closing price on May 13, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.35%
Tags
none
-
Rhea-AI Summary

Guardant Health (Nasdaq: GH) will present real-world data supporting the performance of its Shield™ blood test for colorectal cancer (CRC) screening at the 2024 Digestive Disease Week (DDW) in Washington, DC. The Shield test aims to increase CRC screening rates by offering a more convenient and less unpleasant method compared to traditional options. Presentations will include data showing improved screening rates and early detection of CRC. Initial results from the ECLIPSE study, validating Shield’s performance, were unveiled at the 2023 DDW, leading to a premarket approval (PMA) application to the FDA. An FDA Advisory Panel is set to review this application on May 23, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
conferences
Rhea-AI Summary

Guardant Health reported a 31% increase in revenue for the first quarter of 2024 compared to the same period in 2023. The company achieved significant revenue growth in precision oncology, driven by increased testing volume and reimbursement rates. Despite a decrease in free cash flow, Guardant Health raised its 2024 revenue guidance to $675-$685 million, showcasing a positive outlook for the year. The company also highlighted key milestones achieved in clinical data validation, product launches, and publication impact.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.07%
Tags

FAQ

What does Guardant Health, Inc. specialize in?

Guardant Health specializes in liquid-based cancer tests, providing non-invasive diagnostic tools for clinical and research use.

What are the main products offered by Guardant Health?

Guardant Health offers Guardant360 LDT, Guardant360 CDx, Guardant OMNI, Reveal, and Shield, which are various liquid biopsy tests for cancer detection and treatment selection.

What is Guardant360 CDx?

Guardant360 CDx is an FDA-approved companion diagnostic test used to guide targeted cancer therapies.

How does Guardant Health support cancer research?

Guardant Health aids cancer research through products like Guardant OMNI and services such as regulatory approval consultancy and clinical trial referrals.

What is the significance of the Reveal test?

Reveal is a tumor-agnostic molecular residual disease (MRD) test that helps monitor cancer recurrence or residual disease at the molecular level.

What is the purpose of the Shield test?

The Shield test is a non-invasive liquid biopsy for colorectal cancer (CRC) screening.

Who are some of the major investors in Guardant Health?

Guardant Health has received investments from Sequoia Capital, Khosla Ventures, Orbimed, and SoftBank.

Where is Guardant Health, Inc. headquartered?

Guardant Health, Inc. is headquartered in Redwood City, California.

What is the Guardant360 LDT test used for?

Guardant360 LDT is used for treatment selection in patients with advanced-stage cancer.

How does Guardant Health contribute to early cancer detection?

Guardant Health contributes to early cancer detection through its pioneering products and ongoing research in liquid biopsy technologies.

Guardant Health, Inc.

Nasdaq:GH

GH Rankings

GH Stock Data

3.73B
116.64M
4.15%
92.14%
6.28%
Dental Laboratories
Manufacturing
Link
United States of America
PALO ALTO

About GH

we believe conquering cancer is a big data problem. that’s why we built the world’s leading comprehensive liquid biopsy. this non-invasive tool for accessing and sequencing tumor dna is used by thousands of oncologists to help tens of thousands of advanced cancer patients. we believe the boom in cancer data acquisition we helped launch will drive important discoveries and new products. we’re working on some exciting ones, including in early detection, where the impact on patients can be profound. we’ve raised more than $500 million from investors including sequoia capital, khosla ventures, orbimed, and softbank.